Skip to main content

Table 2 Studies with switch to a different agent after a platinum-based induction

From: Maintenance therapy in NSCLC: why? To whom? Which agent?

First Author (N of randomized pts to maintenance) Maintenance Schema Primary End Point Median PFS (mo) P value Median OS (months) P value References
Fidias P. (309) Immediate vs delayed docetaxel OS 5.7 vs 2.7 0.0001 12.3 vs 9.7 0.08 [26]
Ciuleanu T. (663) Pemetrexed vs placebo PFS 4.3 vs 2.6 0.0001 13.4 vs 10.6 0.012 [27]
Cappuzzo F. (889) Erlotinib vs placebo PFS 12.3 vs 11.1 0.0001 12 vs 11 0.063 [31]
Perol M. (464) Gemcitabine vs erlotinib vs placebo PFS 3.7 vs 2.8 vs 2.1 nr HR 0.86 vs 0.81 na [21]
Kabbinavar F.* (768) Bevacizumab ± Erlotinib PFS 4.8 vs 3.7 0.006 Na na [32]
Gaafar RM (173) Gefitinib vs placebo OS 4.1 vs 2.9 0.0015 Na na [33]
  1. *In this trial bevacizumab was already present in the induction therapy
  2. nr: not reported, na: not available